OBJECTIVE: To evaluate the results of treatment with an insulin glargine-based regimen as compared with those of an NPH insulin-based regimen. METHODS: We reviewed the charts of 83 Japanese patients with Type 1 diabetes treated with insulin glargine for 12 months. PATIENTS: Median age, 56.9 years (range, 24.6-74.8 years), mean (+/-S.D.) body mass index, 21.2 (+/-2.2) kg/m2. RESULTS: The average HbA1c level of the cohort was 7.8 +/- 1.2% at baseline and 7.7 +/- 1.0% at the end of the 12-month treatment (P=0.34). The average insulin requirement per day in the cohort remained unchanged after the 12-month treatment (35.0 +/- 11.6 units/day versus 35.2 +/- 11.2 units/day (P=0.58). Of the 36 patients who were receiving twice or three times daily injections of NPH insulin, 30 could be switched to a single-daily injection of insulin glargine. The frequency of severe hypoglycemia with unconsciousness became lower after switching to the insulin glargine-based regimen than during treatment with the NPH-based regimen. The average ratio of the daily usage of insulin glargine to that of total insulin after 12 months was smaller than that reported from other countries (0.34 +/- 0.09). CONCLUSION: These results obtained from a larger number of patients as compared to previous Japanese studies confirm earlier reports that insulin glargine provides equivalent glycemic control to human NPH insulin, with a lower incidence of severe hypoglycemia. Thus, treatment with insulin glargine provides some benefits to Japanese patients with Type 1 diabetes.
OBJECTIVE: To evaluate the results of treatment with an insulinglargine-based regimen as compared with those of an NPH insulin-based regimen. METHODS: We reviewed the charts of 83 Japanese patients with Type 1 diabetes treated with insulinglargine for 12 months. PATIENTS: Median age, 56.9 years (range, 24.6-74.8 years), mean (+/-S.D.) body mass index, 21.2 (+/-2.2) kg/m2. RESULTS: The average HbA1c level of the cohort was 7.8 +/- 1.2% at baseline and 7.7 +/- 1.0% at the end of the 12-month treatment (P=0.34). The average insulin requirement per day in the cohort remained unchanged after the 12-month treatment (35.0 +/- 11.6 units/day versus 35.2 +/- 11.2 units/day (P=0.58). Of the 36 patients who were receiving twice or three times daily injections of NPH insulin, 30 could be switched to a single-daily injection of insulinglargine. The frequency of severe hypoglycemia with unconsciousness became lower after switching to the insulinglargine-based regimen than during treatment with the NPH-based regimen. The average ratio of the daily usage of insulinglargine to that of total insulin after 12 months was smaller than that reported from other countries (0.34 +/- 0.09). CONCLUSION: These results obtained from a larger number of patients as compared to previous Japanese studies confirm earlier reports that insulinglargine provides equivalent glycemic control to human NPH insulin, with a lower incidence of severe hypoglycemia. Thus, treatment with insulinglargine provides some benefits to Japanese patients with Type 1 diabetes.
Authors: Paulo H R F Almeida; Brian Godman; Vania Dos Santos Nunes-Nogueira; Lívia L P de Lemos; Francisco de Assis Acúrcio; Augusto A Guerra-Junior; Vânia E de Araújo; Alessandra M Almeida; Juliana Alvares-Teodoro Journal: Clin Diabetes Date: 2022
Authors: M Shiramoto; T Eto; S Irie; A Fukuzaki; L Teichert; J Tillner; Y Takahashi; M Koyama; R Dahmen; T Heise; R H A Becker Journal: Diabetes Obes Metab Date: 2014-12-22 Impact factor: 6.577
Authors: Lays P Marra; Vania E Araújo; Thales B C Silva; Leonardo M Diniz; Augusto A Guerra Junior; Francisco A Acurcio; Brian Godman; Juliana Álvares Journal: Diabetes Ther Date: 2016-04-05 Impact factor: 2.945
Authors: M Matsuhisa; M Koyama; X Cheng; Y Takahashi; M C Riddle; G B Bolli; T Hirose Journal: Diabetes Obes Metab Date: 2016-02-01 Impact factor: 6.577